3 hrs ago
Genpact And AstraZeneca PLC Extend Finance And Accounting Services Agreement
The AstraZeneca-Genpact relationship launched in 2009. Through its unique Smart Enterprise Processes methodology for improving the effectiveness of business processes, combined with analytical insights, technology, and global delivery excellence, Genpact has helped AstraZeneca achieve impact through continuous process improvement initiatives and ... (more)
Wed Dec 11, 2013
FDA Advisory Committee Votes on Investigational Medicine Metreleptin
Advisory Committee recommends metreleptin for the treatment of pediatric and adult patients with generalized lipodystrophy; does not recommend for the treatment of partial lipodystrophy for the indication currently proposed )-- AstraZeneca and Bristol-Myers Squibb Company today announced the U.S. Food and Drug Administration's Endocrinologic and ... (more)
Tue Dec 10, 2013
AstraZeneca PLC, Bristol-Myers Squibb Company's Fat Disorder Drug May ...
U.S. Food and Drug Administration staff said on Tuesday they were wary about the benefits versus the risks of AstraZeneca and Bristol-Myers Squibb's new diabetes drug dapagliflozin.
Fri Dec 06, 2013
AstraZeneca Stock Rating Reaffirmed by Citigroup Inc.
's stock had its "neutral" rating restated by equities research analysts at Citigroup Inc. in a research note issued to investors on Friday, Analyst Ratings Net reports.
BRIEF-EU approves AstraZeneca's four-strain flu vaccine Fluenz Tetra
AstraZeneca PLC : * European Commission approves intranasal four-strain influenza vaccine Fluenz Tetra * Follows a positive opinion from the Committee for Medicinal Products for Human Use on 19 September 2013 * Source text for Eikon: * For more news, please click here We welcome comments that advance the story through relevant opinion, anecdotes, ... (more)
Wed Dec 04, 2013
AstraZeneca PLC Said To Be Eyeing Forest Laboratories, Inc. Takeover Bid
AstraZeneca is considering a takeover bid for Forest Laboratories of the US, according to a Financial Times report which cites people close to two companies.
Tue Dec 03, 2013
The Globe and Mail
Apotex ordered to pay AstraZeneca $76-million in damages
A U.S. federal judge has awarded AstraZeneca PLC $76-million in damages from generic drug manufacturer Apotex Inc. for infringing upon patents for AstraZeneca's blockbuster heartburn drug, Prilosec, between 2003 and 2007.
Mon Dec 02, 2013
AstraZeneca Target of Unusually Large Options Trading
Shares of AstraZeneca saw some unusual options trading activity on Friday. Investors purchased 1,621 put options on the company, Analyst Ratings Network.com reports.
Tue Nov 26, 2013
AstraZeneca: A Positive Future Awaits This Company
Biopharmaceutical companies witness their share prices sky rocket following the approval of a drug or a positive review.
Owner of AstraZeneca PLC Site, Loughborough In "Advanced Talks" With Would-Be Tenant
AstraZeneca isn't the only one expanding in jobs, others are hiring too! Check it out! A marketing push is under way to attract world-class businesses to a major science and technology park.
Sat Nov 23, 2013
AstraZeneca Downgraded to "Neutral" at Ubs Ag
They currently have a GBX 3,400 target price on the stock, down from their previous target price of GBX 3,600 .
Volume Sizzlers - AstraZeneca plc (ADR) (NYSE:AZN), Cobalt...
StockMarketIntel.com issues a special report on the following stocks: AstraZeneca plc , Cobalt International Energy, Inc. , CA, Inc. , The Kroger Co.
Fri Nov 22, 2013
Horizon Discovery Ltd. And AstraZeneca PLC Win ???Licensing Deal Of...
Horizon Discovery has won "Licensing Deal of the Year" at the Scrip Awards 2013, for their agreement with AstraZeneca to explore Horizon's first-in-class kinase target program HD-001 as a means of developing novel therapies for multiple cancer types.
Xigduoa (dapagliflozin and metformin hydrochloride) Receives Positive ...
Xigduo a Receives Positive CHMP Opinion in the European Union for the Treatment of Type 2 Diabetes )-- AstraZeneca and Bristol-Myers Squibb today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of Xigduo a for adults aged 18 and older with type 2 ... (more)
Wed Nov 20, 2013
Two former MedImmune execs out at AstraZeneca unit
AstraZeneca PLC has parted ways with Scott Carmer and Tim Gray , two former MedImmune executives who most recently held top positions in AZ's newly created specialty care division, the pharmaceutical giant confirmed this week.
AstraZeneca Given New GBX 3,430 Price Target at Berenberg Bank
The firm currently has a "hold" rating on the stock. Berenberg Bank's price target suggests a potential upside of 3.69% from the company's current price.
Here's who wins in aftermath of Pozen-AstraZeneca drama
John Plachetka, CEO of Chapel Hill-based Pozen, which is now a partner with Horizon Pharma USA Inc. for Vimovo sales in the United States.
NHANES Analyses Reinforce the Need for Education to Help Increased...
AstraZeneca today announced the results of three analyses of data from the National Health and Nutrition Examination Survey , all of which supported that an unmet treatment need still exists for dyslipidemia patients, particularly those at high-risk.
Tue Nov 19, 2013
Research Alert-AstraZeneca: Berenberg cuts price target
AstraZeneca PLC : * Berenberg cuts price target to 3430p from 3472p; rating hold For a summary of rating actions and price target changes on European companies: Reuters Eikon users, click on Reuters 3000Xtra users, double-click Thomson ONE users, type in RT/RCH/EUROPE We welcome comments that advance the story through relevant opinion, anecdotes, ... (more)
AstraZeneca PLC Takes First Big Step For New Global R&D Center,...
AstraZeneca appoints architect for new global R&D centre and corporate headquarters in Cambridge, UK AstraZeneca today announced that it has selected architects Herzog & de Meuron to design its new centre in Cambridge in the UK.